Takeda Pharmaceutical Company Limited (TAK) Q2 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed outlook. Positive aspects include growth in launched products, strategic partnerships, and promising pipeline developments. However, there are concerns about competitive pressures, revised gross margin outlook due to FX impacts, and lack of clarity in management's responses. The Q&A section highlights uncertainties in some areas, such as ENTYVIO's growth and competitive pressures. Overall, the sentiment is balanced between positive developments and potential risks, leading to a neutral prediction.
Key Financial Performance
Revenue in H1 JPY 2.2 trillion, a decrease of 6.9% or minus 3.9% at constant exchange rates (CER). The decline was due to the loss of approximately JPY 100 billion of VYVANSE revenue.
Core Operating Profit (Core OP) JPY 639.2 billion, a year-on-year decrease of 11.2% at actual FX or 8.8% at CER. The decline was mainly due to the loss of exclusivity (LOE) of high-margin VYVANSE and a negative impact from transactional FX, which accounts for about 1/3 of the decline.
Reported Operating Profit JPY 253.6 billion, a decline of 27.7% due to larger impairment losses this fiscal year, including a JPY 58.2 billion expense related to the discontinuation of cell therapy efforts.
Core EPS JPY 279, reflecting a year-on-year decline. The decline was influenced by the loss of exclusivity of VYVANSE and transactional FX impacts.
Reported EPS JPY 72, a 40% decline year-on-year. This reflects the impairment of cell therapy, which is nondeductible from taxable income.
Adjusted Free Cash Flow JPY 525.4 billion, showing strong cash flow performance, including improvements in working capital.
Growth on Launch Products 5.3% at CER. This modest growth includes the impact of phasing of certain products, with higher growth anticipated in the second half.
ENTYVIO Growth 5.1% at CER. Growth was slightly below expectations due to slower-than-expected revenue growth, leading to a revised full-year forecast of 6% at CER.
TAKHZYRO Growth 5.9% at CER, continuing to grow steadily as a market leader in HAE prophylaxis.
PDT Portfolio Growth IG growth was 3.1%, with SCIG portfolio growing at double digits. Albumin declined slightly in H1 due to timing of shipments to China and cost containment measures, but high single-digit growth is expected for both IG and albumin in H2.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
VYVANSE: Significant generic impact in H1 FY2025, with a revenue loss of approximately JPY 100 billion. Expected to have less impact moving forward.
ENTYVIO: Growth of 5.1% at constant exchange rate (CER) in H1 FY2025. Pen usage in the U.S. grew 20% quarter-to-quarter but represents only 9% of ENTYVIO volume. Full-year forecast revised to 6% growth at CER.
TAKHZYRO: Continues to grow steadily as a market leader in HAE prophylaxis with 5.9% growth at CER.
Rusfertide, Oveporexton, Zasocitinib: Three new product launches expected from FY2026 onwards. Positive Phase III studies for rusfertide and oveporexton, with zasocitinib Phase III data in psoriasis expected by the end of calendar year 2025.
Innovent Biologics Partnership: Strategic partnership to expand oncology pipeline with three differentiated assets: IBI363, IBI343, and IBI3001. Potential combined addressable market of over $48 billion.
QDENGA: Reallocated supply based on market needs, with some shipment timing pushed to later in FY2025. Transactional FX, particularly euro appreciation, impacted sales.
Operational Efficiencies: Efficiency improvements include organizational changes affecting 600 positions, real estate optimization, and R&D value chain efficiencies. Restructuring costs in H1 were JPY 27.4 billion.
Cost Discipline: Focused on driving OpEx savings to offset unfavorable product mix and FX impacts. Reduction in R&D and SG&A expenses contributed to mitigating profit decline.
Technology and AI: Leadership in leveraging technology and AI to transform the company.
Cell Therapy Discontinuation: Decision to discontinue cell therapy efforts, resulting in a JPY 58.2 billion impairment loss.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
VYVANSE generic impact: The company faced a significant loss of approximately JPY 100 billion in revenue due to the loss of exclusivity (LOE) for VYVANSE, which has been a major headwind to growth.
Foreign exchange headwinds: Transactional foreign exchange, particularly the euro appreciation, has negatively impacted revenue and profits, especially for products like QDENGA.
Impairment losses: The company booked a nontax deductible impairment loss related to cell therapy discontinuation, which significantly impacted reported operating profit.
ENTYVIO growth challenges: ENTYVIO's revenue growth has been slightly below expectations, leading to a revised full-year forecast of 6% at constant exchange rates.
Medicare Part D redesign: This redesign has impacted several products in the U.S., including GAMMAGARD LIQUID, affecting revenue performance.
Albumin performance in China: Albumin sales declined slightly in H1 due to timing of shipments to China and cost containment measures, though performance is expected to improve in H2.
Operational efficiency challenges: The company is undergoing restructuring, including organizational changes affecting 600 positions and real estate optimization, to drive OpEx savings.
Oncology pipeline risks: The success of the oncology pipeline, including assets from the Innovent Biologics partnership, depends on clinical trial outcomes and regulatory approvals, which are inherently uncertain.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: Revenue in H1 was just over JPY 2.2 trillion, a decrease of 6.9% or minus 3.9% at constant exchange rates (CER). The company expects better growth rates for the full fiscal year, with growth and launch products delivering higher growth in H2 and VYVANSE year-on-year decline moderating.
Margin Projections: Core operating profit for H1 was JPY 639.2 billion, a year-on-year decrease of 11.2% at actual FX or 8.8% at CER. The company expects higher OpEx savings to fully mitigate the impact from unfavorable product mix, though transactional FX dynamics are expected to have a larger impact on profits.
Product Launches and Pipeline: From fiscal year 2026 onwards, Takeda anticipates three new product launches: rusfertide, oveporexton, and zasocitinib. The late-stage pipeline is expected to evolve further, supported by a strategic partnership with Innovent Biologics. The company plans to file for U.S. approval of oveporexton later this year and expects zasocitinib Phase III psoriasis data by the end of the calendar year.
Market Trends and Business Segment Performance: ENTYVIO growth is revised to 6% at CER for the full year. The PDT business is expected to grow at mid-single digits, with immunoglobulin and albumin growing at high single digits. Albumin performance is expected to accelerate in H2. The SCIG portfolio is growing at double digits and is expected to continue. Vaccines, including QDENGA, are expected to meet annual demand estimates despite timing shifts in shipments.
Operational Changes and Efficiency: The company is focused on cost discipline and operational efficiencies, including organizational changes impacting 600 positions and optimization of real estate. Restructuring costs in H1 were JPY 27.4 billion, with further OpEx savings expected.
Capital Expenditures and Financial Adjustments: The adjusted free cash flow forecast includes a USD 1.2 billion payment to Innovent Biologics for an in-licensing deal, funded by cash on hand. The dividend outlook remains JPY 200 per share for the full year.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Outlook: Our dividend outlook remains JPY 200 per share for the full year.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How will Takeda manage R&D expenses for the Innovent assets and their impact on operating margins?
A:Takeda is committed to investing in its oncology portfolio to support long-term growth while maintaining profitability. Financial implications of the Innovent deal are reflected in revised forecasts. Specific R&D spend and margin outlook for fiscal year 2026 are not disclosed, but Takeda aims to achieve mid- to long-term margins through top-line growth and cost optimization. Cost-sharing programs, such as with Blackstone for mezagitamab, are being utilized to manage incremental investments.
Q:What actions is Takeda taking to address currency-related earnings changes?
A:Currency fluctuations, particularly euro volatility, have significantly impacted earnings. Takeda is considering long-term strategies, such as rebalancing its manufacturing footprint, to mitigate currency risks. However, these are long-term plans and not immediate actions.
Q:What is Takeda doing to enhance ENTYVIO Pen penetration and address insurance coverage challenges?
A:Takeda is improving access at multiple levels, including signing contracts with major PBMs and addressing localized challenges. ENTYVIO Pen has seen 20% quarter-over-quarter growth, and specific tactical actions are being implemented to overcome access hurdles.
Q:What is the significance of Takeda's collaboration with Nabla Bio?
A:The collaboration with Nabla Bio leverages AI in drug discovery to optimize large molecule sequences. Takeda has successfully conducted pilot experiments with Nabla, leading to accelerated programs and novel discoveries. This partnership aligns with Takeda's strategy to use advanced technologies in research.
Q:What factors contributed to the revised gross margin outlook for Takeda?
A:The gross margin outlook was revised downward due to transactional FX impacts and product mix changes, including reduced revenue from VYVANSE and ENTYVIO. These factors are expected to lower gross margins in the second half of the fiscal year.
Q:When is the next data update for IBI363 expected, and when will the global Phase III trial start?
A:Takeda has not disclosed the timing for the next data update for IBI363. The global Phase III trial for second-line squamous non-small cell lung cancer is expected to begin in the coming months.
Q:What are the competitive pressures affecting ENTYVIO's growth, and what is Takeda's outlook?
A:ENTYVIO faces intensified competition, particularly in Crohn's Disease (CD), and slower-than-expected pen conversion due to access hurdles. Despite these challenges, ENTYVIO remains the market leader in IBD, and Takeda expects growth to accelerate as access issues are resolved.
Q:How confident is Takeda in replicating impressive China data for IBI363 in international trials?
A:Takeda conducted extensive due diligence, including evaluations by its radiologists, and found strong correlations with response criteria. Enrollment in global trials, including in the U.S. and Australia, is ongoing, and Takeda is optimistic about replicating the data.
Q:What is the mechanism of action for IBI363, and how does it address concerns about Treg activation?
A:IBI363 uses an IL-2 alpha-biased approach to target tumor-specific T cells without activating Tregs, which could suppress the immune response. Clinical data align with this mechanism, showing encouraging results in IO-refractory and earlier-line settings.
Q:What is Takeda's strategy for the plasma-derived therapies (PDT) business in the U.S. and globally?
A:Takeda is focusing on improving efficiency and productivity in its BioLife collections network rather than opening new centers. It is also exploring opportunities to expand plasma collection outside the U.S. to ensure sustainable supply.
Q:How does Takeda plan to sustain or increase its dividend payments despite downward guidance revisions?
A:Takeda's dividend policy is based on core EPS, reported EPS, and long-term debt reduction. Decisions on dividends will be announced in May, considering these parameters.
Q:What is the current state of the albumin market in China, and how is Takeda addressing challenges?
A:Albumin sales in China declined due to shipment phasing and government-imposed cost controls. Takeda is expanding albumin opportunities outside China and has secured tenders in other markets to drive growth.
Q:What are Takeda's ambitions for its celiac disease programs?
A:Takeda has two ongoing Phase II programs for celiac disease: TAK-227 and TAK-101. These programs aim to address the unmet medical need in celiac disease, but the bar for success is high, and data will determine their potential.
Q:What is the target product profile for mezagitamab in IgAN?
A:Mezagitamab aims to offer efficacy comparable to competitors with potential treatment holidays and better safety. Upcoming 96-week data will provide more insights.
Q:What is Takeda's outlook for ENTYVIO's growth and peak sales?
A:Takeda expects ENTYVIO to maintain its market share in IBD despite competitive pressures. Growth is expected to align with market trends, and peak revenue guidance remains unchanged.
Q:What is the potential of IBI3001, and how does its mechanism work?
A:IBI3001 targets EGFR and B7H3 using a novel exatecan payload. It aims to deliver precise and effective treatment for GI and thoracic cancers, leveraging its dual-target mechanism.
Q:Review of Unclear Management Responses
A:Management avoided providing specific timelines for the next data update for IBI363 and the exact outlook for R&D spend and margins for fiscal year 2026. Additionally, responses to questions about the U.S. Biosecure Act's impact on the Innovent deal and potential changes to the MarsLight-11 trial design were vague and lacked detail.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ADC
ASCO
Bitetti
CER
GI cancer
Global
Greater China
IBI
IO
IgA nephropathy
Innovent Biologics
Milano
NT
Oncology
PD
Phase III
Takeda
alpha
asset
bispecific
cell lung
collaboration
concept
currency
deal
designation
detail Innovent
launch product
lung cancer
mechanism
microsatellite cancer
oncology
oveporexton
standard care
symptom
tumor
TAK Transcript
Takeda Pharmaceutical Company Limited (TAK) Q4 2026 Earnings Call Transcript
Unknown5-13
The earnings call summary lacks detailed information on key financial metrics, strategic initiatives, and operational updates, with no explicit mention of revenue, margins, or cash flow. The Q&A section also lacks substantive insights. Although the strategic plan indicates potential for growth with new product launches and pipeline development, the absence of concrete financial data or guidance tempers expectations. This results in a neutral sentiment rating, as the lack of clarity and specifics limits the ability to predict a significant stock price movement.
Takeda Pharmaceutical Company Limited (TAK) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-4
Coveo Solutions Inc. (CVO:CA) Q3 2026 Earnings Call Transcript
Positive1-30
The earnings call summary shows improvements in cash flow and a strong cash position, with no debt, indicating financial health. The Q&A highlights strong customer relationships and growth in key sectors, with a strategic partnership with SAP. Despite a cautious Q4 guidance, the overall sentiment is positive due to strong bookings, operational efficiency, and promising market trends. These factors suggest a positive stock price movement over the next two weeks.
Takeda Pharmaceutical Company Limited (TAK) Q3 FY2025 Earnings Call Transcript
Unknown1-30
The earnings call summary and Q&A reveal mixed signals. Revenue growth is modest, with some segments like QDENGA performing well, but others like TAKHZYRO facing competition. The company's strategic partnership and new product launches are positive but lack immediate impact. Uncertainty in guidance and potential pricing pressures from IRA negotiations further contribute to a neutral outlook. The dividend policy remains stable, but no clear shareholder return enhancement is evident. Overall, the lack of strong catalysts and mixed financial performance suggest a neutral stock price movement in the short term.
TAK Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
